| Status: AWMSG assessment in progress | |
Treatment of osteoporosis in men at increased risk of fracture |
|
Medicine details |
|
| Medicine name | teriparatide |
| Formulation | 20 micrograms/80 microlitres solution for injection |
| Reference number | 6561 |
| Indication | as above |
| BNF chapter | Endocrine system |
| Submission type | Limited |
| Status | AWMSG assessment in progress |
| Scrutiny Panel meeting date | 06/02/2025 |
| LOWMAG meeting date | 07/05/2025 |
| AWMSG meeting date | 18/06/2025 |
| Further information The AWMSG Scrutiny Panel considered teriparatide suitable for a limited reassessment (teriparatide was originally assessed for use in men in 2008, see ref 306) |
|